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Lack of Access to HIV/AIDS Drugs in Developing Countries:
Is There a Violation of the International Human Right to Health?
by Barbara Cochrane Alexander*

. . . a number of pharmaceutical
corporations appear opposed to
governments’ independent attempts to
improve their countries’ access to
HIV/AIDS drugs.

12

international trade law. Specifically, Pharmaceuticals Manufacturers
Association v. the President of South Africa, Case No. 4183/98,
contested South Africa’s 1997 Medicines and Related Substances Control Amendment Act, which allows South Africa to
import and produce less expensive, generic versions of
HIV/AIDS drugs. The lawsuit has delayed the implementation
of this law. By extension, the lawsuit challenges South Africa’s
efforts to protect and promote the international human right
to health. As a signatory to the International Covenant on
Economic, Social and Cultural Rights (ICESCR), South Africa
is taking steps to fulfill the ICESCR’s international health
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he Joint United Nations Programme on HIV/AIDS
(UNAIDS) reported an estimated 36 million people worldwide are afflicted with HIV/AIDS in its December 2000
AIDS epidemic update, of which 25.3 million live in sub-Saharan
Africa. In response to the spread of the HIV/AIDS epidemic over
the past decade, pharmaceutical corporations have tested their
HIV/AIDS drugs in developing countries. Unfortunately, these
countries often cannot afford to purchase the drugs pharmaceutical corporations test on their citizens. The issue of affordable HIV/AIDS drugs is a primary obstacle to access. While not
the only obstacle—others include underdeveloped healthcare
infrastructure, and a lack of HIV testing, education, and prevention programs—making HIV/AIDS drugs affordable for
developing countries is a necessary part of successful efforts to fight
the AIDS epidemic. Over the past 12 to 15 months, affordability
as a primary obstacle impeding access to HIV/AIDS drugs in developing countries has received increased attention from the international community and mass media.
On February 20, 2001, UN Secretary General Kofi Annan
released a 29-page report in which he highlighted the important
role pharmaceutical corporations have in providing affordable
access to HIV/AIDS drugs in developing countries. Following this
report, in March 2001, a number of pharmaceutical corporations,
including Bristol Myers Squibb, Merck, and GlaxoSmithKline,
agreed to provide their drugs at lower costs for developing countries. On April 5, 2001, Annan met with chief executives of six of
the world’s largest pharmaceutical corporations and urged them
to lower the costs of HIV/AIDS drugs even further for certain
African countries. The prices remain too high, and poor persons
in developing countries most likely still will be unable to afford
the drugs without the help of charities and government agencies.
Furthermore, a number of pharmaceutical corporations appear
opposed to governments’ independent attempts to improve their
countries’ access to HIV/AIDS drugs. According to the Washington
Post, Annan acknowledged the importance of patent protections
but said he expected the companies to become “partners in the
fight against AIDS.”
In a case just recently dropped by the plaintiffs, 39 pharmaceutical corporations sued the South African government for its
effort to import and produce cheaper generic HIV/AIDS drugs,
which corporations allege violates their patent rights under

Placing a box containing the ashes of a baby who died from HIV/
AIDS into a wall of remembrance in Johannesburg, South Africa.

obligations, even though until ratification it is not legally
required to do so. Under General Comment 14’s interpretation
of Article 12 of the ICESCR, the international human right to
health includes access to “facilities, goods, services and conditions necessary for the realization of the highest attainable
standard of health.”
In the context of this right to health, several relevant questions arise. First, do developing countries violate this right
when they fail to provide access to HIV/AIDS drugs for their citizens? The ICESCR takes into account developing countries’ limited resources while mandating their progressive realization of
the right to health over time. This progressive realization
requires developing countries, if party to the ICESCR, to take
steps toward full realization.
Related to this first question is the issue of the responsibility of developed countries for violations of the international
human right to health under the ICESCR. Developed countries,
in which most pharmaceutical corporations manufacturing
and marketing HIV/AIDS drugs are located, may also have
international health obligations to developing countries. If a
developed country is a State Party to the ICESCR, it may violate
the right to health by failing to influence pharmaceutical corporations’ actions that restrict access to HIV/AIDS drugs in
developing countries.
Finally, do pharmaceutical corporations’ actions that block
access to HIV/AIDS drugs violate the right to health? Although,
generally, corporate responsibility in public international law
currently is an underdeveloped and untested theory, there is
growing support that public international law can apply to
private actors. Pharmaceutical corporations eagerly enter
continued on next page
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developing countries to test their drugs with fewer restrictions than in developed countries. Although there are
internationally accepted ethical guidelines governing
clinical trials in developing countries, even these ethical
guidelines are not always followed. Controversies surrounding aspects of study design and continued drug
access post-clinical trials highlight how pharmaceutical
corporations fail to follow ethical guidelines. For these reasons, among others, even though the legal argument for
corporate responsibilities toward developing countries’
right to health is not strong, it is worth improving. In practice, corporations and individual States’ acts or omissions
significantly impact the international human right to
health in developing countries.
Lack of Access to HIV/AIDS Drugs as a Violation of the
International Human Right to Health
There are a number of international legal instruments relevant to the international human right to health. The international human rights community’s ongoing attempts to define
the scope of a right to health have evolved through the UN Charter, the Universal Declaration of Human Rights (UDHR), the
Constitution of the World Health Organization, and the ICESCR, among others. Article 12 of the ICESCR creates legal
obligations for State Parties to take steps toward realizing that
the right to health, including those States Parties currently
unable to fully realize the right to health because of limited
resources. Most recently, the UN Committee on Economic,
Social, and Cultural Rights (Committee) further explained
ICESCR Article 12’s international human right to health in
General Comment No. 14: “The Right to the Highest Attainable
Standard of Health” (General Comment).
ICESCR and General Comment No. 14
A number of provisions in Article 12 of the ICESCR are relevant to the HIV/AIDS epidemic and the issue of access to
HIV/AIDS drugs. First, Article 12(1) requires “State Parties to
the present Covenant recognize the rights of everyone to the
enjoyment of the highest attainable standard of physical and
mental health . . . .” Further, Article 12(2)(c) requires States Parties to take steps for “[t]he prevention, treatment and control
of epidemic, endemic, occupational and other diseases.” Additionally, State Parties must create “conditions which would
assure to all medical service and medical attention in the event
of sickness” (Article 12(2)(d)). In order to better explain the
right to health, the Committee promulgated the General Comment.
According to the General Comment, the scope of Article 12’s
right to health includes the right to the highest attainable standard of health; the right to affordable, quality healthcare; and
the right to equality of access to health services. The “highest
attainable standard of health” considers “the individual’s biological and socio-economic preconditions and a State’s available
resources.” This standard suggests developing countries have different “highest attainable standards” than developed countries.
Nevertheless, it does not preclude developing countries from
raising their highest available standards in efforts to realize
more fully the right to health. Access to HIV/AIDS drugs is significant for improving quality of life, protecting the ability to
exercise other human rights and, in certain cases, helping to stop
the transmission of the disease. Therefore, it is necessary to close
the gap between developing and developed countries’ highest
attainable standards. Additionally, within the context of
HIV/AIDS research, Article 15(1)(b) of the ICESCR is also
relevant. It states everyone has the right “to enjoy the benefits
of scientific progress and its applications.” While the General
Comment recognizes a State cannot ensure the good health of

its citizens, it explains that State Parties must take the necessary
steps for the realization of the highest attainable standard of
health. Regarding HIV/AIDS drugs, these steps, under the
ICESCR, also include an obligation by States Parties to assist their
citizens in gaining access to HIV/AIDS drugs, which exist as a
benefit of scientific progress.

Pharmaceutical corporations eagerly enter
developing countries to test
their drugs with fewer restrictions than in
developed countries. Although there are
internationally accepted ethical guidelines
governing clinical trials in developing
countries, even these ethical guidelines are
not always followed.
As the Committee explains in the General Comment, “[t]he
right to health, like all human rights, imposes three types or levels of obligations on States Parties: the obligation to respect, protect and fulfil.” These obligations require States Parties “to
refrain from interfering directly or indirectly with the enjoyment
of the right to health” (respect); “to take measures that prevent
third parties from interfering with Article 12 guarantees” (protect); and “to adopt appropriate legislative, administrative, budgetary, judicial, promotional and other measures toward the full
realization of the right to health” (fulfil). These rights and
obligations suggest developing countries must provide access,
or at least attempt to provide access, to HIV/AIDS drugs for their
citizens as part of the right to health.
Currently, South Africa is only a signatory to the ICESCR.
Although it is not legally bound until it ratifies the ICESCR,
South Africa is still a useful example: it shows how developing
countries progressively can realize and fulfil their legal obligations to protect the right to health of their citizens. First, by seeking to limit pharmaceutical corporations’ patent rights, as the
1997 Medicines and Related Substances Control Amendment
Act does, South Africa is taking measures to prevent interference
by third-party pharmaceutical corporations and to protect the
right to health. Second, by legislating for the importation and
production of cheaper generic HIV/AIDS drugs, South Africa
arguably is attempting to improve access to HIV/AIDS drugs for
its citizens. According to the General Comment, acts or omissions of State Parties unable to comply with Article 12 obligations due to resource constraints, but making “every effort . . .
to use all available resources at its disposal in order to satisfy,
as a matter of priority, the obligations of [Article 12 of the
ICESCR],” are not in violation of the right to health. Other ICESCR State Parties, developed countries in particular, however,
do not benefit from the limited resources exception and arguably
have additional responsibilities.
States Parties as Violators for Failing to Control Third Parties
In addition to direct violations of the international human
right to health by ICESCR State Parties, the General Comment
suggests State Parties also might be responsible for violations of
the international human right to health caused by third parties
in their jurisdictions. In the General Comment, the Committee
provides that “State parties have to respect the enjoyment of the
right to health in other countries, and to prevent third parties from
violating the right in other countries, if they are able to influence these
third parties by way of legal or political means, in accordance with
continued on next page

13

Access to HIV/AIDS Drugs, continued from previous page

the Charter of the United Nations and applicable international
law” (emphasis added). Within this understanding of the scope
of State Parties’ legal obligations, pharmaceutical corporations
can be characterized as third parties. Since States can regulate
or attempt to regulate pharmaceutical corporations and their
research and marketing, they should do so to prevent violations
of the right to health. For example, States can choose not to fund
pharmaceutical research if the pharmaceutical corporation
does not follow fundamental biomedical research guidelines.
Additionally, States can promote freedom of speech and expression to allow individuals and interest groups to apply pressure
to pharmaceutical corporations to lower their costs or provide
drugs at no cost. If the United States were a State Party to the
ICESCR, its failure to prevent its pharmaceutical corporations
from blocking South Africa’s access to HIV/AIDS drugs could
violate the right to health.
Moreover, in its General Comment, the Committee proceeds even further to include an affirmative obligation for State
Parties to protect the right to health. The General Comment provides that “[d]epending on the availability of resources, States
should facilitate access to essential health facilities, goods and
services in other countries wherever possible and provide the
necessary aid when required.” This interpretation of State Parties’ international obligations serves as a call to resource-rich,
developed countries to assist developing countries unable to
comply with Article 12 obligations. It includes the possibility of
working more closely with pharmaceutical corporations to provide HIV/AIDS drugs at low or no cost to persons living in
developing countries.
Third-Party Pharmaceutical Corporations as Violators of the
International Human Right to Health
The legal argument for corporate human rights liability for
violations of the right to health resulting from lack of access to
HIV/AIDS drugs is not strong. Public international law traditionally applies to public, State actors rather than private, individual actors. There is, however, some legal precedent upon
which to build a stronger legal argument for corporate human
rights liability. At least two international legal instruments set
forth the possibility of corporate responsibility for human rights
violations.
First, the UDHR, which has the force of customary international law, states in its Preamble that “every organ of society . . .
shall strive . . . to promote respect for these rights and freedoms
and . . . to secure their universal and effective recognition.” A
pharmaceutical corporation arguably is an “organ of society.”
Further, if the drafters of the UDHR intended to limit the
scope of who should promote and recognize human rights to
public, state actors, they could have used the phrase “every
State” rather than “every organ of society.” Second, there is the
UN Declaration on the Right and Responsibility of Individuals,
Groups and Organs of Society to Promote and Protect Universally Recognized Human Rights and Fundamental Freedoms
(Human Rights Defenders Declaration). This Declaration is
aspirational and reaffirms the UDHR. It states in Article 18, Paragraph 2, that “[i]ndividuals, groups, institutions and non-governmental organizations have an important role to play and a
responsibility in safeguarding democracy, promoting human
rights and fundamental freedoms and contributing to the promotion and advancement of democratic societies, institutions
and processes.” Unfortunately, pharmaceutical corporations
are unlikely to agree that they have any legal responsibility
regarding an international human right to health.
Additionally, pharmaceutical corporations testing their
HIV/AIDS drugs in developing countries often disagree over
their ethical responsibilities. Ideally, the international human
14

rights community should be able to use biomedical research
ethics and human rights as complementary tools to strengthen
the international human right to health. Unfortunately, these
ethical disagreements do not provide a solid foundation from
which to strengthen the legal responsibilities of pharmaceutical corporations. In the context of what type of access clinical
trial participants should have to any available standard therapies,
for example, two differing opinions predominate. One opinion
is that study participants should have access to the best-proven
standard therapies available anywhere in the world. Persons who
hold this opinion argue against placebo/treatment research. A
recent trial highlighting the controversy of placebo/treatment
research was a perinatal HIV vertical transmission clinical trial.
This trial was designed to test a less intensive and cheaper regimen of zidovudine, a drug that prevents the transfer of HIV to
infants during birth. The trial contained a placebo arm, which
meant some HIV-positive mothers participating in the study did
not receive a known treatment to prevent HIV-transmission to
their unborn children during birth. A second opinion asserts
that study participants should have access to the highest attainable standard available based on resources (local standard). Pharmaceutical corporations argue that the economic realities of
developing countries make it unrealistic for them to provide
access to the best-proven standard therapies available elsewhere
in the world. Certain ethical guidelines, however, suggest this
point is not as relevant to the debate as pharmaceutical corporations claim.
In 1993, the Council for International Organizations of
Medical Sciences (CIOMS) published International Ethical Guidelines for Biomedical Research Involving Human Subjects, specifically
citing as its impetus in its Background Note “the prospect of field
trials of vaccines and drugs to control AIDS.” Guideline 8
addresses “Research involving subjects in underdeveloped communities.” In particular, it provides “[a]s a general rule, the sponsoring agency should ensure that, at the completion of successful
testing, any product developed will be made reasonably available to inhabitants of the underdeveloped community in which
the research was carried out . . . .” Additionally, paragraph 30
of the World Medical Association’s Declaration of Helsinki
states, “[a]t the conclusion of the study, every patient entered
into the study should be assured of access to the best proven prophylactic, diagnostic and therapeutic methods identified by
the study.” These ethical research guidelines have relevance to
developing a legal argument that third-party pharmaceutical corporations violate the right to health when they block access to
HIV/AIDS drugs in developing countries. They establish ethical responsibility for pharmaceutical corporations to provide
drug access at least to the countries in which they conducted
their research. Furthermore, the term “sponsoring agency”
could also apply to State actors financially sponsoring pharmaceutical corporations’ research in developing countries.
Conclusion
Although the international human rights community needs
to strengthen its legal arguments, lack of access to HIV/AIDS
drugs in developing countries does violate the international
human right to health. It is particularly important to strengthen
the legal arguments for non-state/third-party actors’ responsibilities. Pharmaceutical corporations feel vilified by criticisms
that they value patents more than human lives, but perhaps they
fail to realize that limited price reductions of drug treatments
are not sufficient to address the scope of the HIV/AIDS
epidemic. 
*Barbara Cochrane Alexander is a J.D. candidate at the Washington College of Law and a staff writer for the Human Rights Brief.

